{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:38:47Z","timestamp":1785497927388,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40272-021-00459-x","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T02:02:27Z","timestamp":1630375347000},"page":"515-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Laboratory Safety of Dupilumab in Patients Aged 6\u201311 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial"],"prefix":"10.1007","volume":"23","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Arkwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh","family":"Vakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karli","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-5121","authenticated-orcid":false,"given":"Noah A.","family":"Levit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"issue":"3","key":"459_CR1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.15928","volume":"178","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Eyerick K, de Bruin-Weller M, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768\u201375.","journal-title":"Br J Dermatol"},{"issue":"1","key":"459_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10\u201322.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"459_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"459_CR4","first-page":"125","volume":"6","author":"T Frantz","year":"2019","unstructured":"Frantz T, Wright EG, Balogh EA, Cline A, Adler-Neal AL, Feldman SR. Topical and oral therapies for childhood atopic dermatitis and plaque psoriasis. Children (Basel). 2019;6(11):125.","journal-title":"Children (Basel)."},{"issue":"1","key":"459_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jan.13818","volume":"75","author":"J McLenon","year":"2019","unstructured":"McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. 2019;75(1):30\u201342.","journal-title":"J Adv Nurs"},{"issue":"14","key":"459_CR6","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111(14):5147\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"459_CR7","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Poburshy K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"459_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"issue":"24","key":"459_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10086","key":"459_CR10","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"5","key":"459_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to cyclosporine A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"issue":"2","key":"459_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"459_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"459_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.18476","volume":"182","author":"MJ Cork","year":"2020","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85\u201396.","journal-title":"Br J Dermatol"},{"issue":"5","key":"459_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"459_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120\u201335.","journal-title":"Br J Dermatol"},{"issue":"2","key":"459_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40257-020-00583-3","volume":"22","author":"E Siegfried","year":"2021","unstructured":"Siegfried E, Bieber T, Simpson EL, Paller A, Beck LA, Boguniewicz M, et al. Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized placebo-controlled phase 3 clinical trial. Am J Clin Dermatol. 2021;22(2):243\u201355.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"459_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S0190-9622(03)02539-8","volume":"49","author":"L Eichenfield","year":"2003","unstructured":"Eichenfield L, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003;49(6):1088\u201395.","journal-title":"J Am Acad Dermatol"},{"key":"459_CR19","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE); Version 5.0. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 11 Feb 2021."},{"key":"459_CR20","unstructured":"Nordic study group on myeloproliferative disorders (NMPD). Guidelines for the diagnosis and treatment of eosinophilia. 2nd version. 2012. http:\/\/www.myeloid.dk\/filearchive\/baae3847cc11e0dab52ab8b8f09e8122.pdf. Accessed 11 Feb 2021."},{"issue":"4","key":"459_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2332\/allergolint.O-08-537","volume":"57","author":"R Tamagawa-Mineoka","year":"2008","unstructured":"Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of \u03b2-thromboglobulin and platelet factor 4. Allergol Int. 2008;57(4):391\u20136.","journal-title":"Allergol Int"},{"issue":"2","key":"459_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdermsci.2014.10.003","volume":"77","author":"R Tamagawa-Mineoka","year":"2015","unstructured":"Tamagawa-Mineoka R. Important roles of platelets as immune cells in the skin. J Dermatol Sci. 2015;77(2):93\u2013101.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"459_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jaad.2019.04.036","volume":"81","author":"PM Brunner","year":"2019","unstructured":"Brunner PM, He H, Pavel AB, Czarnowicki T, Lefferdink R, Erickson T, et al. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. J Am Acad Dermatol. 2019;81(2):510\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"459_CR24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Gulewicz KJ, Wang CQF, et al. Progressive activation of Th2\/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344\u201354.","journal-title":"J Allergy Clin Immunol"},{"key":"459_CR25","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"K Rabe","year":"2018","unstructured":"Rabe K, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475\u201385.","journal-title":"N Engl J Med"},{"key":"459_CR26","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"issue":"10209","key":"459_CR27","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350.","journal-title":"Lancet"},{"issue":"7","key":"459_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545\u201353.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"459_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","volume":"68","author":"S Furuta","year":"2019","unstructured":"Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68(4):430\u20136.","journal-title":"Allergol Int"},{"issue":"5","key":"459_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204.","journal-title":"Allergy"},{"key":"459_CR31","doi-asserted-by":"publisher","first-page":"abstractA5555","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5555","volume":"199","author":"J Allinne","year":"2019","unstructured":"Allinne J, Scott G, Birchard D, Asrat S, Nagashima K, Le Floc\u2019h A, et al. Broader impact of IL-4R\u03b1 blockade than IL-5 blockade on mediators of type 2 inflammation and lung pathology in a house dust mite-induced asthma mouse model. Am J Respir Crit Care Med. 2019;199:abstractA5555. https:\/\/doi.org\/10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5555.","journal-title":"Am J Respir Crit Care Med"},{"key":"459_CR32","doi-asserted-by":"publisher","first-page":"abstractPA77","DOI":"10.1183\/13993003.congress-2018.PA977","volume":"52","author":"J Orengo","year":"2018","unstructured":"Orengo J, Allinne J, Le Floc\u2019h A, Potocky T, Kim JH, Birchard D, et al. Blocking IL-4Ra with dupilumab prevents lung inflammation in a mouse asthma model. Eur Respir J. 2018;52:abstractPA77. https:\/\/doi.org\/10.1183\/13993003.congress-2018.PA977.","journal-title":"Eur Respir J"},{"issue":"1","key":"459_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"459_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x","volume":"17","author":"H Mukai","year":"1990","unstructured":"Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol. 1990;17(8):477\u201381.","journal-title":"J Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00459-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T15:12:46Z","timestamp":1630768366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00459-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00459-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"23 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT03345914. The study sponsors participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication. Medical writing\/editorial assistance were provided by Vicki Schwartz, PhD, of Excerpta Medica, and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline: .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amy S. Paller has served as a scientific advisor and\/or clinical study investigator for AbbVie, Abeona Therapeutics, Almirall, AnaptysBio, Asana Biosciences, Boehringer Ingelheim, BridgeBio, Dermavant, Dermira, Eli Lilly, Exicure, Fort\u00e9, Galderma, Incyte, InMed Pharmaceuticals, Janssen, LEO Pharma, LifeMax, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Sol Gel, and UCB. Andreas Wollenberg has been an investigator for Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and UCB; has been a consultant for AbbVie, Almirall, Anacor Pharmaceuticals, Arena Pharmaceuticals, Eli Lilly, Galapagos, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; and has received research grants from LEO Pharma and Pierre Fabre. Elaine Siegfried has served as a scientific advisor and\/or clinical study investigator for Eli Lilly, Janssen, Novan, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, UCB, and Verrica Pharmaceuticals; as a paid speaker for Regeneron Pharmaceuticals, Inc.; and as a data and safety monitoring board member for GSK, LEO Pharma, Novan, Pfizer, and UCB. Diamant Tha\u00e7i has been a consultant, advisory board member, and\/or investigator for AbbVie, Almirall, Amgen, Beiersdorf, Boehringer Ingelheim, Dermira, Eli Lilly, Galapagos, Galderma, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, and UCB. Michael J. Cork has received research grants from Astellas Pharma, Atopix, Galopagos, Harvey Water Softeners, Hyphens Pharma, Johnson & Johnson, Kymab, L\u2019Or\u00e9al, LEO Pharma, Novartis, Oxagen, Perrigo (ACO Nordic), Pfizer, Reckitt Benkiser, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; has been a consultant and\/or advisory board member for Astellas Pharma, Atopix, Boots, Dermavent, Galderma, Galopagos, Hyphens Pharma, Johnson & Johnson, Kymab, L\u2019Or\u00e9al, LEO Pharma, Menlo, Novartis, Oxagen, Perrigo (ACO Nordic), Pfizer, Proctor & Gamble, Reckitt Benkiser, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and UCB; and has served as a voluntary medical advisor to the National Eczema Society, UK. Peter D. Arkwright has served as an advisory board member for and received consulting fees and project grant funding from Sanofi Genzyme; and is an investigator for Regeneron Pharmaceuticals, Inc. Melinda Gooderham has received consulting fees\/honoraria from AbbVie, Akros Pharma, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Coherus BioSciences, Dermira, Eli Lilly, Galderma, GSK, Janssen, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Sun Pharma, UCB, and Valeant Pharmaceuticals\/Bausch; has received fees for participation in review activities from AbbVie, Akros Pharma, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, UCB, and Valeant Pharmaceuticals\/Bausch; has received payment for lectures and\/or service on speakers bureaus from AbbVie, Amgen, Biosciences, Boehringer Ingelheim, Dermira, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Sun Pharma, UCB, and Valeant Pharmaceuticals\/Bausch; and has served as an investigator, advisor, and\/or speaker for AbbVie, Akros Pharma, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Coherus BioSciences, Dermira, Eli Lilly, Galderma, GSK, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Sanofi Genzyme, Sun Pharma, UCB, and Valeant Pharmaceuticals\/Bausch. Xian Sun, Faisal A. Khokhar, Ashish Bansal, Brad Shumel, and Noah A. Levit are employees and shareholders of Regeneron Pharmaceuticals, Inc. John T. O\u2019Malley and Jignesh Vakil are employees of and may hold stock and\/or stock options in Sanofi. Karli Rosner is an employee of and may hold stock and\/or stock options in Sanofi Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study was conducted following the ethical principles that derive from the Declaration of Helsinki, International Council for Harmonisation guidelines, Good Clinical Practice guideline, and local applicable regulatory requirements. The trial was overseen by an independent data and safety monitoring board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients and the patients\u2019 parents\/guardians prior to commencement of any study treatment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that written consent was obtained from parents or legal guardians for publishing study information and results.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB, KR, BS, and NAL contributed to study concept and design. ASP, AW, ES, DT, MJC, PDA, and MG acquired data. XS conducted the statistical analyses on the data. KR and NAL drafted the manuscript with the medical writer and created figures. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}